Name: Mocetinostat (MGCD0103, MG0103)
Price: 241.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Mocetinostat, also known as MGCD0103 or MG0103, is an isotype-selective inhibitor of human histone deacetylases (HDAC), a family of enzymes involved in epigenetic regulation of gene transcription as well as cell proliferation, death and motility. Mocetinostat potently inhibits HDAC class I (HDAC1, HDAC2, and HDAC3) and class IV (HDAC11), with values of inhibition constant IC50 of 0.15 μmol/L, 0.29 μmol/L, 1.66 μmol/L, and 0.59 μmol/L respectively, rather than HDAC class II. Mocetinostat exerts anti-tumor activity against a broad range of human cancer cells through HDAC inhibition, in which it induces histone hyperacetylation and apoptosis and causes cell cycle blockade in a dose-dependent manner.
- Properties
  - Alternative Name
    
    MGCD-0103; N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
    
    CAS Number
    
    726169-73-9
    
    Molecular Formula
    
    C23H20N6O
    
    Molecular Weight
    
    396.44
    
    Appearance
    
    A solid
    
    Purity
    
    99.44%
    
    Solubility
    
    insoluble in EtOH; insoluble in H2O; ≥19.8 mg/mL in DMSO
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Topper MJ, Vaz M, et al. "Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer." Cell. 2017 Nov 30;171(6):1284-1300.e21. PMID:29195073
    2. Bagnall NH, Hines BM, et al. "Insecticidal activities of histone deacetylase inhibitors against a dipteran parasite of sheep, Lucilia cuprina." Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):51-60. PMID:28110187

Mocetinostat (MGCD0103, MG0103)

Mocetinostat (MGCD0103, MG0103)

Background

We Also Recommend

CUDC-101

JNJ-26481585

PCI-34051